Table 3. Associations of Antidepressants Use and Gastric Cancer Risk.
| Antidepressants | Cases (n = 49342) | Controls (n = 240985) | OR | |||
|---|---|---|---|---|---|---|
| Crude (95%CI a ) | Adjusted b (95% CI) | |||||
| N | % | N | % | |||
| SSRI c | ||||||
| ≧28DDD | 598 | 2.27 | 3261 | 2.55 | 0.88 (0.80–0.96) | 0.87 (0.78–0.96) |
| ≧84DDD | 343 | 1.30 | 1936 | 1.51 | 0.84 (0.75–0.95) | 0.86 (0.75–0.97) |
| ≧168DDD | 240 | 0.91 | 1317 | 1.03 | 0.87 (0.76–1.00) | 0.90 (0.78–1.05) |
| ≧336DDD | 139 | 0.53 | 817 | 0.64 | 0.81 (0.68–0.97) | 0.86 (0.71–1.04) |
| SNRI d | ||||||
| ≧28DDD | 47 | 0.18 | 268 | 0.21 | 0.83 (0.61–1.13) | 0.87 (0.63–1.20) |
| ≧84DDD | 36 | 0.14 | 182 | 0.14 | 0.94 (0.66–1.35) | 0.99 (0.69–1.43) |
| ≧168DDD | 19 | 0.07 | 125 | 0.10 | 0.73 (0.45–1.18) | 0.77 (0.47–1.26) |
| ≧336DDD | 13 | 0.05 | 75 | 0.06 | 0.83 (0.46–1.51) | 0.90 (0.50–1.64) |
| TCA e | ||||||
| ≧28DDD | 882 | 3.36 | 4358 | 3.41 | 0.96 (0.89–1.04) | 0.89 (0.82–0.96) |
| ≧84DDD | 432 | 1.64 | 1958 | 1.53 | 1.06 (0.95–1.17) | 0.99 (0.89–1.10) |
| ≧168DDD | 214 | 0.81 | 1010 | 0.79 | 1.01 (0.87–1.18) | 0.96 (0.83–1.12) |
| ≧336DDD | 93 | 0.35 | 415 | 0.32 | 1.08 (0.86–1.35) | 1.05 (0.84–1.33) |
| RIMA f | ||||||
| ≧28DDD | 161 | 0.61 | 781 | 0.61 | 1.00 (0.84–1.18) | 1.00 (0.84–1.19) |
| ≧84DDD | 82 | 0.31 | 421 | 0.33 | 0.94 (0.74–1.19) | 0.96 (0.75–1.22) |
| ≧168DDD | 47 | 0.18 | 252 | 0.20 | 0.90 (0.66–1.22) | 0.94 (0.69–1.30) |
| ≧336DDD | 28 | 0.11 | 132 | 0.10 | 1.02 (0.68–1.53) | 1.10 (0.73–1.67) |
| Mirtazapine | ||||||
| ≧28DDD | 19 | 0.07 | 91 | 0.07 | 0.99 (0.60–1.62) | 1.05 (0.64–1.74) |
| ≧84DDD | 9 | 0.03 | 49 | 0.04 | 0.88 (0.43–1.79) | 0.94 (0.46–1.92) |
| ≧168DDD | 5 | 0.02 | 26 | 0.02 | 0.91 (0.35–2.36) | 1.00 (0.38–2.63) |
| ≧336DDD | 2 | 0.01 | 10 | 0.01 | 0.94 (0.21–4.31) | 1.06 (0.23–4.87) |
| Trazodone | ||||||
| ≧28DDD | 305 | 1.16 | 1449 | 1.13 | 1.00 (0.89–1.14) | 1.00 (0.87–1.13) |
| ≧84DDD | 117 | 0.45 | 630 | 0.49 | 0.88 (0.72–1.06) | 0.90 (0.73–1.10) |
| ≧168DDD | 38 | 0.14 | 290 | 0.23 | 0.62 (0.44–0.87) | 0.64 (0.45–0.90) |
| ≧336DDD | 13 | 0.05 | 88 | 0.07 | 0.69 (0.39–1.24) | 0.74 (0.41–1.33) |
| Bupropion | ||||||
| ≧28DDD | 9 | 0.03 | 37 | 0.03 | 1.16 (0.56–2.40) | 1.19 (0.57–2.48) |
| ≧84DDD | 2 | 0.01 | 23 | 0.02 | 0.40 (0.09–1.69) | 0.41 (0.10–1.75) |
| ≧168DDD | 1 | 0.00 | 12 | 0.01 | 0.39 (0.05–3.03) | 0.41 (0.05–3.18) |
| ≧336DDD | 0 | 0.00 | 5 | 0.00 | - | - |
a confidence interval
b Adjusting with urbanization, income, hypertension, diabetes, hypercholesterolemia, chronic kidney disease, peptic ulcer and depressive disorder.
c SSRI: selective serotonin re-uptake inhibitors
d SNRI: Serotonin–norepinephrine reuptake inhibitors
e TCA: tricyclic antidepressants
f RIMA: Reversible inhibitors of monoamine oxidase A